ZA202108950B - Oxymetazoline compositions and methods for treating ocular disorders - Google Patents
Oxymetazoline compositions and methods for treating ocular disordersInfo
- Publication number
- ZA202108950B ZA202108950B ZA2021/08950A ZA202108950A ZA202108950B ZA 202108950 B ZA202108950 B ZA 202108950B ZA 2021/08950 A ZA2021/08950 A ZA 2021/08950A ZA 202108950 A ZA202108950 A ZA 202108950A ZA 202108950 B ZA202108950 B ZA 202108950B
- Authority
- ZA
- South Africa
- Prior art keywords
- oxymetazoline
- compositions
- methods
- ocular disorders
- treating ocular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962843819P | 2019-05-06 | 2019-05-06 | |
| US201962844069P | 2019-05-06 | 2019-05-06 | |
| US16/716,014 US10799481B1 (en) | 2019-05-06 | 2019-12-16 | Compositions and methods for treating ocular disorders |
| US16/715,998 US10814001B1 (en) | 2019-05-06 | 2019-12-16 | Oxymetazoline compositions |
| PCT/US2020/031425 WO2020227260A1 (en) | 2019-05-06 | 2020-05-05 | Oxymetazoline compositions and methods for treating ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202108950B true ZA202108950B (en) | 2023-10-25 |
Family
ID=72750169
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/08950A ZA202108950B (en) | 2019-05-06 | 2021-11-11 | Oxymetazoline compositions and methods for treating ocular disorders |
| ZA2022/12328A ZA202212328B (en) | 2019-05-06 | 2022-11-11 | Oxymetazoline compositions and methods for treating ocular disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/12328A ZA202212328B (en) | 2019-05-06 | 2022-11-11 | Oxymetazoline compositions and methods for treating ocular disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (11) | US10814001B1 (enExample) |
| EP (1) | EP3965737A1 (enExample) |
| JP (3) | JP7141420B2 (enExample) |
| KR (3) | KR102410503B1 (enExample) |
| CN (2) | CN111888326B (enExample) |
| AU (1) | AU2020268329A1 (enExample) |
| BR (1) | BR112021022404A2 (enExample) |
| CA (1) | CA3139443A1 (enExample) |
| CL (1) | CL2021002918A1 (enExample) |
| CO (1) | CO2021015265A2 (enExample) |
| IL (1) | IL287831A (enExample) |
| MA (1) | MA55895A (enExample) |
| MX (1) | MX2021013516A (enExample) |
| PE (1) | PE20220384A1 (enExample) |
| SG (1) | SG11202112272TA (enExample) |
| WO (1) | WO2020227260A1 (enExample) |
| ZA (2) | ZA202108950B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| US10814001B1 (en) * | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| US20240156786A1 (en) | 2021-03-03 | 2024-05-16 | Voom, Llc | Compositions and methods for treatment of blepharitis |
| WO2023079427A1 (en) * | 2021-11-03 | 2023-05-11 | Avaca Pharma Private Limited | Ophthalmic compositions and methods thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE51421B1 (en) | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5888493A (en) | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| DE10337186A1 (de) * | 2003-08-13 | 2005-03-17 | Merck Patent Gmbh | Wässrige Wirkstoff-Lösung |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| JP2006131628A (ja) * | 2004-10-08 | 2006-05-25 | Rohto Pharmaceut Co Ltd | オキシメタゾリン含有水性組成物 |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| TWI454286B (zh) | 2006-03-17 | 2014-10-01 | Johnson & Johnson Vision Care | 安定氧化性不安定組合物之方法 |
| CA2650592A1 (en) | 2006-04-26 | 2007-11-08 | Aciex, Inc. | Compositions for the treatment and prevention of eyelid swelling |
| US8466203B2 (en) * | 2006-12-06 | 2013-06-18 | David Choohyun Paik | Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds |
| MX2010006932A (es) * | 2007-12-21 | 2010-10-05 | Schering Plough Healthcare | Aumento de la fotoestabilizacion de la oximetazolina. |
| CA2717605C (en) * | 2008-03-11 | 2012-05-15 | Alcon Research Ltd. | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
| CA2764477A1 (en) * | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations, methods of manufacture, and methods of using same |
| US20120082625A1 (en) | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| WO2012063237A2 (en) * | 2010-11-08 | 2012-05-18 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
| CA2819633C (en) | 2010-12-03 | 2019-04-23 | Allergan, Inc. | Pharmaceutical cream compositions and methods of use |
| US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| JP2015518006A (ja) | 2012-05-25 | 2015-06-25 | エクスクリア インコーポレイテッド | キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 |
| UA119324C2 (uk) | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| WO2015040086A1 (en) | 2013-09-18 | 2015-03-26 | Mycronic AB | Method, system and device for handling pallets in an smt system |
| WO2015191917A1 (en) | 2014-06-11 | 2015-12-17 | Allergan, Inc. | Stabilized oxymetazoline formulations and their uses |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| US20170312335A1 (en) * | 2015-12-30 | 2017-11-02 | Lubris Llc | Topical use of prg4 for treatment of allergy and symptoms of inflammation |
| CN115006537A (zh) | 2016-01-26 | 2022-09-06 | 利维申制药有限公司 | α-肾上腺素能药剂的组合物和用途 |
| CN105997856A (zh) * | 2016-06-24 | 2016-10-12 | 魏威 | 盐酸羟甲唑啉滴眼液及其制备方法 |
| US11246816B2 (en) | 2016-06-30 | 2022-02-15 | The Procter And Gamble Company | Shampoo compositions comprising a chelant |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
-
2019
- 2019-12-16 US US16/715,998 patent/US10814001B1/en active Active
- 2019-12-16 US US16/716,014 patent/US10799481B1/en active Active
-
2020
- 2020-03-16 JP JP2020045468A patent/JP7141420B2/ja active Active
- 2020-04-01 CN CN202010249167.7A patent/CN111888326B/zh active Active
- 2020-04-01 CN CN202310901249.9A patent/CN117045596A/zh active Pending
- 2020-04-27 KR KR1020200050837A patent/KR102410503B1/ko active Active
- 2020-05-05 MX MX2021013516A patent/MX2021013516A/es unknown
- 2020-05-05 PE PE2021001852A patent/PE20220384A1/es unknown
- 2020-05-05 BR BR112021022404A patent/BR112021022404A2/pt unknown
- 2020-05-05 CA CA3139443A patent/CA3139443A1/en active Pending
- 2020-05-05 WO PCT/US2020/031425 patent/WO2020227260A1/en not_active Ceased
- 2020-05-05 EP EP20729894.4A patent/EP3965737A1/en active Pending
- 2020-05-05 MA MA055895A patent/MA55895A/fr unknown
- 2020-05-05 SG SG11202112272TA patent/SG11202112272TA/en unknown
- 2020-05-05 AU AU2020268329A patent/AU2020268329A1/en active Pending
- 2020-10-05 US US17/063,416 patent/US10940138B2/en active Active
- 2020-10-07 US US17/064,915 patent/US10898573B1/en active Active
-
2021
- 2021-01-21 US US17/154,676 patent/US11103482B2/en active Active
- 2021-03-08 US US17/194,559 patent/US11324722B2/en active Active
- 2021-08-30 US US17/461,052 patent/US11311515B2/en active Active
- 2021-09-24 JP JP2021155526A patent/JP7705326B2/ja active Active
- 2021-11-04 IL IL287831A patent/IL287831A/en unknown
- 2021-11-05 CL CL2021002918A patent/CL2021002918A1/es unknown
- 2021-11-11 CO CONC2021/0015265A patent/CO2021015265A2/es unknown
- 2021-11-11 ZA ZA2021/08950A patent/ZA202108950B/en unknown
-
2022
- 2022-04-25 US US17/728,860 patent/US11541036B2/en active Active
- 2022-05-09 US US17/662,494 patent/US11701343B2/en active Active
- 2022-06-14 KR KR1020220072209A patent/KR102663319B1/ko active Active
- 2022-11-11 ZA ZA2022/12328A patent/ZA202212328B/en unknown
- 2022-12-23 US US18/146,127 patent/US20230355587A1/en active Pending
-
2023
- 2023-06-08 US US18/331,688 patent/US20240033250A1/en active Pending
-
2024
- 2024-04-29 KR KR1020240057166A patent/KR102859351B1/ko active Active
-
2025
- 2025-01-31 JP JP2025014721A patent/JP2025065198A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202212328B (en) | Oxymetazoline compositions and methods for treating ocular disorders | |
| PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| EP4445954A3 (en) | Cellular models of and therapies for ocular diseases | |
| WO2016172712A3 (en) | Ophthalmic composition | |
| MX2018010788A (es) | Composicion oftalmologica. | |
| WO2016183424A8 (en) | Light adjustable intraocular lenses using upconverting nanoparticles and near infrared (nir) light | |
| EA201591743A8 (ru) | СТИМУЛЯТОРЫ sGC | |
| EP4397375A3 (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2021004280A (es) | Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. | |
| EP4420726A3 (en) | Fixed dose combination of bromonidine and timolol | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| MX2023002113A (es) | Composicion que contiene dioxido de cloro y metodos para su uso. | |
| MY198195A (en) | Composition For Suppressing Or Improving Eye Fatigue | |
| CL2019002839A1 (es) | Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3. | |
| PH12021550372A1 (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| MX377725B (es) | Combinación que comprende un compuesto de aminotioléster o una de sus sales farmacéuticamente aceptables y un compuesto capaz de aumentar el nivel de peróxido de hidrógeno (h2o2) en las células cancerosas de un sujeto. | |
| EA202190751A1 (ru) | Способы лечения миелопролиферативных расстройств | |
| TW201613596A (en) | Ophthalmic suspension preparation | |
| MY207807A (en) | "cosmetic anti-blemish composition, use of said composition, method of anti-blemish treatment, and applicator device". | |
| MX2018013324A (es) | Métodos y composiciones para el tratamiento del síndrome de rett. | |
| GEP20207144B (en) | Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof | |
| MX2023001950A (es) | Compuestos y formulaciones para el tratamiento de enfermedades oftalmicas. |